Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 4/20 | 0.30 |
| ▸ | NOS1 | P29475 | 4/20 | 0.30 |
| ▸ | NOS2 | P35228 | 4/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29689054 | 0.99 | CHEK1 (0.31) | CHEK2CHEK1KDM4EALDH1A1GAA | |
| SCHEMBL20135148 | 0.86 | CHEK1 (0.41) | CHEK2CHEK1NOS3NOS1NOS2 | |
| SCHEMBL20135063 | 0.79 | CHEK1 (0.33) | CHEK2CHEK1NOS3NOS1NOS2 | |
| SCHEMBL20134889 | 0.79 | CHEK1 (0.33) | CHEK2CHEK1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL29688904 | 0.78 | CHEK1 (0.32) | CHEK2CHEK1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL29688682 | 0.78 | CHEK1 (0.32) | CHEK2CHEK1NOS3NOS1NOS2 | |
| SCHEMBL20135028 | 0.77 | CHEK2 (0.51) | CHEK2CHEK1BTK | |
| SCHEMBL20134866 | 0.73 | CHEK1 (0.42) | CHEK2CHEK1 | |
| SCHEMBL20134820 | 0.72 | CHEK2 (0.38) | CHEK2CHEK1BTK | |
| Hydrochloric Acid SCHEMBL29688666 | 0.72 | CHEK1 (0.42) | CHEK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | CHEK2 4437/4885CHEK1 4792/4885KDM4E 725/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | CHEK2 4390/4885CHEK1 4797/4885KDM4E 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.